AU4162402A - Process - Google Patents

Process

Info

Publication number
AU4162402A
AU4162402A AU4162402A AU4162402A AU4162402A AU 4162402 A AU4162402 A AU 4162402A AU 4162402 A AU4162402 A AU 4162402A AU 4162402 A AU4162402 A AU 4162402A AU 4162402 A AU4162402 A AU 4162402A
Authority
AU
Australia
Prior art keywords
compounds
ammonium
azasteroids
steriods
hydrogenation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU4162402A
Other languages
English (en)
Inventor
Roman Davis
Alan Millar
Jeffrey Thomas Sterbenz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU4162402A publication Critical patent/AU4162402A/xx
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Glass Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Valve Device For Special Equipments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU4162402A 2000-11-03 2001-11-02 Process Pending AU4162402A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0026876.3A GB0026876D0 (en) 2000-11-03 2000-11-03 Process
PCT/US2001/048173 WO2002046207A2 (en) 2000-11-03 2001-11-02 Process

Publications (1)

Publication Number Publication Date
AU4162402A true AU4162402A (en) 2002-06-18

Family

ID=9902484

Family Applications (2)

Application Number Title Priority Date Filing Date
AU4162402A Pending AU4162402A (en) 2000-11-03 2001-11-02 Process
AU2002241624A Ceased AU2002241624B2 (en) 2000-11-03 2001-11-02 Process

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2002241624A Ceased AU2002241624B2 (en) 2000-11-03 2001-11-02 Process

Country Status (24)

Country Link
US (1) US6794508B2 (de)
EP (1) EP1335930B1 (de)
JP (1) JP4257117B2 (de)
KR (1) KR100821018B1 (de)
CN (1) CN1313480C (de)
AT (1) ATE279429T1 (de)
AU (2) AU4162402A (de)
BR (1) BR0115089A (de)
CA (1) CA2427709A1 (de)
DE (1) DE60106482T2 (de)
DK (1) DK1335930T3 (de)
ES (1) ES2230383T3 (de)
GB (1) GB0026876D0 (de)
HK (1) HK1058799A1 (de)
HU (1) HUP0303907A3 (de)
IL (2) IL155078A0 (de)
MX (1) MXPA03003925A (de)
NO (1) NO325180B1 (de)
NZ (1) NZ525168A (de)
PL (1) PL206539B1 (de)
PT (1) PT1335930E (de)
SI (1) SI1335930T1 (de)
WO (1) WO2002046207A2 (de)
ZA (1) ZA200302560B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100503193B1 (ko) 2002-08-19 2005-07-25 한미약품 주식회사 3-옥소-4-아자-5α-안드로스탄 화합물의 선택적인 제조방법
WO2005075497A1 (en) * 2004-01-07 2005-08-18 Ranbaxy Laboratories Limited PROCESS FOR THE PREPARATION OF 17ß-SUBSTITUTED-3-OXO-4-AZA-5ALPHA-ANDROSTANE DERIVATIVES
CN100355772C (zh) * 2005-12-28 2007-12-19 天津大学 具有5α－还原酶抑制活性的甾体化合物及其制备方法
AR070313A1 (es) * 2008-01-03 2010-03-31 Gador Sa Un procedimiento para preparar una forma solida y cristalina de dutasteride, una forma polimorfica del compuesto (forma iii) y una composicion farmaceutica que incluye dicha forma
HU230730B1 (hu) 2011-06-30 2017-12-28 Richter Gedeon Nyrt Eljárás (5alfa,17béta)-N-[2,5-bisz-(trifluormetil)-fenil]-3-oxo-4-aza-5-androszt-1-én-17-karbonsavamid előállítására
CN103059097A (zh) * 2011-10-20 2013-04-24 连云港润众制药有限公司 一种度他雄胺中间体的制备方法
CN103254268A (zh) * 2013-05-16 2013-08-21 寿光市富康化学工业有限公司 一种制备度他雄胺的工艺
CN104231033B (zh) * 2014-09-17 2016-08-24 广东众生药业股份有限公司 一种度他雄胺的制备方法
CN108051513B (zh) * 2017-11-27 2020-09-29 重庆华邦制药有限公司 Hplc法分离测定度他雄胺起始原料sm2及其相关杂质的方法
CN109438549B (zh) * 2018-12-13 2022-01-04 湖北葛店人福药业有限责任公司 一种制备N-叔丁基-3-氧代-4-氮杂-5α-雄甾-17β-甲酰胺的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74365A (en) * 1984-02-27 1990-07-26 Merck & Co Inc 17beta-(n-t.-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one and pharmaceutical compositions containing it
GB2264494A (en) * 1992-02-25 1993-09-01 Merck & Co Inc 17b-n-monosubstituted carbamoyl-11-oxo-4-aza-5-a-androst-1-en-3-one testosterone-5-alpha reductase inhibitors
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones

Also Published As

Publication number Publication date
WO2002046207A2 (en) 2002-06-13
IL155078A (en) 2009-06-15
IL155078A0 (en) 2003-10-31
MXPA03003925A (es) 2003-08-19
DE60106482D1 (de) 2004-11-18
NO20031995D0 (no) 2003-05-02
KR20030081326A (ko) 2003-10-17
CA2427709A1 (en) 2002-06-13
NO325180B1 (no) 2008-02-11
KR100821018B1 (ko) 2008-04-08
SI1335930T1 (en) 2005-04-30
GB0026876D0 (en) 2000-12-20
WO2002046207A3 (en) 2003-03-20
PT1335930E (pt) 2005-01-31
ATE279429T1 (de) 2004-10-15
PL365705A1 (en) 2005-01-10
NZ525168A (en) 2005-03-24
JP2004515505A (ja) 2004-05-27
US6794508B2 (en) 2004-09-21
DE60106482T2 (de) 2005-10-13
CN1473165A (zh) 2004-02-04
AU2002241624B2 (en) 2004-10-28
CN1313480C (zh) 2007-05-02
EP1335930B1 (de) 2004-10-13
BR0115089A (pt) 2003-10-07
NO20031995L (no) 2003-05-02
EP1335930A2 (de) 2003-08-20
PL206539B1 (pl) 2010-08-31
ES2230383T3 (es) 2005-05-01
JP4257117B2 (ja) 2009-04-22
HUP0303907A2 (hu) 2004-03-01
ZA200302560B (en) 2004-04-01
HUP0303907A3 (en) 2012-09-28
HK1058799A1 (en) 2004-06-04
US20040049042A1 (en) 2004-03-11
DK1335930T3 (da) 2005-02-14

Similar Documents

Publication Publication Date Title
BRPI0113670B8 (pt) composição farmacêutica e método para tratar hipogonadismo
DE69726577D1 (en) Kristallin form i von clarithromycin
AU4162402A (en) Process
PT971705E (pt) Formulacoes de farmacos de terapeutica de substituicao hormonal para aplicacao topica na pele
WO2001095856A3 (en) Urea derivative useful as an anti-cancer agent and process for preparing same
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
AU5915100A (en) Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
GB0216001D0 (en) Process and composition
SE1212311T3 (de)
ZA985993B (en) Pharmaceutical compositions
EE200300305A (et) Geelkompositsioon ja kompositsiooni transskrotaalne kasutamine hüpogonadismi raviks
AU2001231849A1 (en) Use of dehydroepiandrosterone and/or precursors or derivatives thereof to improve papery aspect of the skin
AU4621500A (en) Novel aluminosiloxane compound and process for preparing the same
WO2002072003A3 (en) Use of steroid derivatives for the treatment of a benighn and/or malignant tumour
AU2001274138A1 (en) Propanolaminotetralines, preparation thereof and compositions containing same
DE60039122D1 (de) 6-o-alkyl-2-nor-2-substituierte ketolidderivate
WO2002048079A3 (de) Verfahren zur herstellung von cis-2-tertiär-butylcyclohexanol
AU2002215996A1 (en) Phenanthridine derivatives and antitumoral medicaments containing phenanthridine
GB957541A (en) 5ª‡-steroids
AU6684500A (en) Novel c-19-halogen-substituted steroids of the androst-9(11)-ene-series, methodsfor the production and use thereof
AU4289600A (en) 14,15-.alpha.-methylene equilenine derivatives, methods for producing the same and medicaments containing them
ECSP003799A (es) Nuevos esteroides con actividad androgenica y su uso como anticonceptivos masculinos y para tratar la insuficiencia androgenica.